{"schema_version":"secwatch.filing_event.v1","accession":"0001576885-25-000102","form_type":"8-K","ticker":"ABOS","cik":"0001576885","company_name":"Acumen Pharmaceuticals, Inc.","filed_at":"2025-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.803852+00:00","generated_at":"2026-05-16T21:12:06.821223+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Acumen reports Q3 net loss $26.5M; cash $136.1M supports ops into early 2027","bullets":["Cash, equivalents & marketable securities $136.1M at Sept 30, down from $166.2M at June 30; runway into early 2027.","Net loss $26.5M vs $29.8M YoY; R&D expense fell to $22.0M from $27.2M.","First patient dosed in November 2025 in open-label extension of Phase 2 ALTITUDE-AD trial of sabirnetug.","Expect non-clinical data for EBD candidate in early 2026; Phase 2 topline results in late 2026.","Added biopharma veteran George Golumbeski as Chairman, board expanded to 8 members."],"urls":{"canonical":"https://secwatch.observer/filing/0001576885-25-000102","json":"https://secwatch.observer/filing/0001576885-25-000102.json","markdown":"https://secwatch.observer/filing/0001576885-25-000102.md","text":"https://secwatch.observer/filing/0001576885-25-000102.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1576885/000157688525000102/0001576885-25-000102-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1576885/000157688525000102/abos-20251112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T21:12:06.821223+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}